Phase 2 trial finds bezisterim shows safety and symptom gains in long COVID, with strongest benefits for severe fatigue, PEM, and cognitive issues.
|Slideshows|May 25, 2021
Going Maskless
Author(s)Leah Kuntz
Over a third of older Americans aren't comfortable taking off their masks until 2022.
Advertisement
Advertisement
Related to this article
Advertisement
Advertisement
Trending on Psychiatric Times
1
When Antidepressants Stop Working: Understanding Tachyphylaxis in Clinical Practice
2
What Do Patient-Level Studies Tell Us About Antidepressants and Suicide Risk?
3
Evidence-Based Ethical Principles for Long-Acting Injectable Antipsychotic Use
4
Sleep Disruption and Alzheimer Disease: A Bidirectional, Treatable Relationship
5